Becketts advises Telix Pharmaceuticals on its acquisition of Dedicaid GmbH

Telix is an ASX-listed (ASX: TLX) biopharmaceuticals company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe and Japan.

Dedicaid GmbH (Dedicaid) is a spin-off of the Medical University Vienna, whose main asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use with positron emission tomography and other imaging modalities.

The acquisition of Dedicaid accelerates the development of Telix’s AI platform and provides the ability to rapidly generate CDSS applications that are highly complementary to Telix’s existing radiopharmaceutical pipeline.

The Becketts team advising Telix included Alex Bean, Partner, supported by Rachel Morris, Senior Associate and Brad Papaluca, Lawyer.